DataSheet1_Predictive biomarkers of mortality in patients with severe COVID-19 hospitalized in intensive care unit.docx

ObjectivesThis study was performed to identify predictive markers of worse outcomes in patients with severe COVID-19 in an intensive care unit.
MethodsSixty patients with severe COVID-19, hospitalized in the Intensive Care Unit (ICU) between March and July 2021, were stratified into two groups according to the outcome survivors and non-survivors. After admission to the ICU, blood samples were collected directly for biomarker analysis. Routine hematological and biochemical biomarkers, as well as serum levels of cytokines, chemokines, and immunoglobulins, were investigated.
ResultsLymphopenia, neutrophilia, and thrombocytopenia were more pronounced in non-surviving patients, while the levels of CRP, AST, creatinine, ferritin, AST, troponin I, urea, magnesium, and potassium were higher in the non-surviving group than the survival group. In addition, serum levels of IL-10, CCL2, CXCL9, and CXCL10 were significantly increased in patients who did not survive. These changes in the biomarkers evaluated were associated with increased mortality in patients with severe COVID-19.
ConclusionThe present study confirmed and expanded the validity of laboratory biomarkers as indicators of mortality in severe COVID-19.